Onconova Moving Forward with Phase 3 INSPIRE Pivotal Trial, Increases Patient  Size From 225 To 360 Patients, Predefined Subgroup Of Very High Risk Patients Constitutes Greater Than 70% Of Patients Enrolled To Date